Ten common errors in the management of inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 9, Issue 3, 2003, Pages 205-209

  Sachar, David B ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; ANTIDIARRHEAL AGENT; ANTIMETABOLITE; AZATHIOPRINE; CYCLOSPORIN; ENEMA; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; SALAZOSULFAPYRIDINE; SPASMOLYTIC AGENT; STEROID;

ARTICLE; CANCER MORTALITY; CANCER RISK; COLORECTAL CANCER; CROHN DISEASE; DIETARY FIBER; DOSE RESPONSE; DRUG MISUSE; DRUG SAFETY; DRUG USE; ENTERITIS; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINE BIOPSY; INTESTINE RADIOGRAPHY; INTESTINE SURGERY; MEDICAL DECISION MAKING; PATIENT CARE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; REMISSION; SUPPOSITORY; TOTAL PARENTERAL NUTRITION; TOXIC MEGACOLON; TREATMENT INDICATION; ULCERATIVE COLITIS; UNITED STATES;

ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; CYCLOSPORINE; HUMANS; INFLAMMATORY BOWEL DISEASES; PRACTICE GUIDELINES; STEROIDS;

EID: 0038054562     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200305000-00011     Document Type: Article

References (29)

1. Bayless TM, Harris ML. Inflammatory bowel disease and irritable bowel syndrome. Med Clin N Am 1990;74:21-8.
2. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993;118:540-9.
3. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987;317:1625-9.
4. Singleton J, Gitnick G, Hanauer S, et al. Response of Crohn's disease to oral Pentasa (controlled release mesalamine) as a function of disease location and prior therapy: results of a multicenter study. Gastroenterology 1993;104:1293-1300.
5. Sachar DB. Maintenance therapy in ulcerative colitis and Crohn's disease. J Clin Gastroenterol 1995;20:117-22.
6. Safdi M, deMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997;92: 1867-71.
7. D'Albasio G, Pacini F, Cawam E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997;92:1143-7.
8. Present DH. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 2000;6:48-57.
9. Sylvester FA, Hyams JS. Appropriate use of corticosteroids in inflammatory bowel disease. In: Bayless TM, Hanauer SB, eds. Advanced Therapy for Inflammatory Bowel Disease. London: BC Decker; 2001:363-66.
10. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance in Crohn's disease: a placebo-controlled dose-ranging study. Gastroenterology 1996;110:45-51.
11. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine with prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
12. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporine in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94:1587-92.
13. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide. Am J Gastroenterol 2002;97:2962-72.
14. Colonna T, Korelitz BI. The role of leukopenia in the 6-mercaptopurine- induced remission of refractory Crohn's disease. Am J Gastroenterol 1994;89:362-6.
15. Modigliani R. Immunosuppressors for inflammatory bowel disease: how long is long enough? Inflamm Bowel Dis 2000;6:251-7.
16. Francella A, Dyan A, Bodian C, et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003; 124: 9-17.
17. Feagan BG, Rochou J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995;332:292-7.
18. Feagan BG, Fedorak RN, Irvine EJ, et al. Comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med 2000;342:1627-32.
19. Baert F, Noman M, Vermeire K, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
20. Kornbluth A. Cyclosporine in inflammatory bowel disease. Curr Gastroenterol Rep 1999;1:486-90.
21. Bernstein CN, Blanchard JF, Houston DS, et al. The incidence of deep vein thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001;85:430-4.
22. Mogan GR, Sachar DB, Bauer J, et al. Toxic megacolon in ulcerative colitis complicated by pneumomediastinum: report of two cases. Gastroenterology 1980;79:159-62.
23. Greenstein AJ, Sachar DB, Gibas A, et al. Outcome of toxic dilation in ulcerative and Crohn's colitis. J Clin Gastroenterol 1985; 7:137-43.
24. Rubin PH, Friedman S. Harpaz N, et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology 1999;117:1295-1300.
25. Engelsgjed M, Farraye FA, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology 1999;117:1288-94.
26. Lindberg B, Persson H, Veress H, et al. Twenty years' colonoscopic surveillance of patients with ulcerative colitis: detection of dysplastic and malignant transformation. Scand J Gastroenterol 1996;31:1195-1204.
27. Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994;107:934-44.
28. Ullman TA. Loftus EV Jr, Kakar S, et al. The fate of low grade dysplasia in ulcerative colitis. Am J Gastroetnerol 2002;97:922-7.
29. Sachar DB. Indications for surgery in inflammatory bowel disease: a gastroetnerologist's opinion. In: Kirsner JB, ed. Inflammatory Bowel Disease. 5th ed. Philadelphia: Saunders; 2000:611-5.